Beets for Liver Phase 2 Support

Beets support hepatic detoxification through two distinct, complementary mechanisms. First, the betalain pigments — particularly betanin — activate the Nrf2/Keap1 antioxidant response pathway, inducing transcription of the canonical phase 2 detoxification enzymes (glutathione S-transferase, NAD(P)H quinone dehydrogenase 1, heme oxygenase-1, glutamate-cysteine ligase) that conjugate and excrete electrophilic xenobiotics. Second, beets are among the densest dietary sources of betaine (trimethylglycine), a methyl donor that supports the betaine-homocysteine methyltransferase (BHMT) pathway, lowers homocysteine, and protects against hepatic steatosis. Animal models show that beetroot feeding protects against acetaminophen-induced liver injury, carbon-tetrachloride hepatotoxicity, and high-fat-diet-induced fatty liver, with consistent upregulation of Nrf2 target genes and increased hepatic glutathione. This page walks through the Nrf2 mechanism, the BHMT/methyl-donor pathway, the experimental and clinical evidence, and how beets fit into a broader liver-support strategy.

Table of Contents

1. Phase 1 vs Phase 2 — A Quick Detoxification Primer
2. The Nrf2/Keap1 Antioxidant Response Pathway
3. Betanin as an Nrf2 Activator
4. The Phase 2 Enzymes Induced by Betalain
5. Betaine as a Methyl Donor — The BHMT Pathway
6. Protection Against NAFLD and Hepatic Steatosis
7. Animal Models — APAP, CCl₄, and High-Fat Diet
8. Clinical Applications and Practical Dosing
9. Cautions and Drug Interactions
10. Key Research Papers
11. Connections

Phase 1 vs Phase 2 — A Quick Detoxification Primer

The liver processes xenobiotics (foreign chemicals, drugs, pollutants, hormones for clearance, endogenous waste) through a two-phase enzymatic system. Phase 1 is dominated by the cytochrome P450 superfamily of monooxygenase enzymes (CYP1A2, CYP2D6, CYP3A4, and dozens of others), which add a polar functional group (typically a hydroxyl) to the lipophilic xenobiotic via oxidation, reduction, or hydrolysis. Phase 1 makes the compound more water-soluble but in many cases produces a reactive intermediate that is more toxic than the parent compound.

Phase 2 then takes that reactive intermediate and conjugates it with a hydrophilic endogenous molecule — glucuronic acid, sulfate, glycine, taurine, glutathione, or methyl groups. The resulting conjugate is highly water-soluble and is excreted in bile or urine. The major phase 2 enzyme families are:

• Glutathione S-transferases (GSTs) — conjugate glutathione (GSH) to electrophilic carbon atoms, the workhorse pathway for clearing reactive oxidative metabolites
• UDP-glucuronosyltransferases (UGTs) — conjugate glucuronic acid, the major pathway for steroid hormone clearance and many drug metabolites
• Sulfotransferases (SULTs) — conjugate sulfate, important for catecholamine and steroid metabolism
• N-acetyltransferases (NATs) — conjugate acetate, important for aromatic amine clearance
• Methyltransferases (COMT, TPMT, others) — transfer methyl groups, important for catecholamine inactivation and many drug metabolisms

The critical clinical reality is that phase 2 capacity is often the rate-limiting step. When phase 1 produces reactive intermediates faster than phase 2 can conjugate them, the intermediates accumulate, react with proteins, lipids, and DNA, and cause hepatotoxicity. Acetaminophen overdose is the classic example — CYP2E1 produces NAPQI (N-acetyl-p-benzoquinone imine) faster than GST can conjugate it with glutathione, glutathione stores are depleted, and free NAPQI causes massive hepatocyte necrosis. N-acetylcysteine, the standard antidote, works by restoring glutathione substrate availability for GST.

Anything that upregulates phase 2 enzymes — increases their expression levels in liver and other tissues — improves the safety margin between phase 1 metabolism and conjugation. This is the rationale behind broccoli sprouts (sulforaphane), cruciferous vegetables (indole-3-carbinol), green tea (EGCG), turmeric (curcumin), and as we will see, beets (betalain pigments and betaine).

Back to Table of Contents

The Nrf2/Keap1 Antioxidant Response Pathway

The master transcriptional regulator of phase 2 enzyme induction is Nrf2 (Nuclear factor erythroid 2–related factor 2), a basic leucine-zipper transcription factor that binds to the antioxidant response element (ARE) consensus sequence in the promoters of more than 200 cytoprotective genes. Under basal conditions, Nrf2 is bound in the cytoplasm by its negative regulator Keap1 (Kelch-like ECH-associated protein 1), which targets Nrf2 for ubiquitination and proteasomal degradation. This keeps cellular Nrf2 levels low when stress is absent.

When the cell encounters oxidative or electrophilic stress, the reactive species modify critical cysteine residues on Keap1 (Cys151, Cys273, Cys288 in human Keap1). The modification disrupts the Keap1-Nrf2 interaction, Nrf2 escapes degradation, and free Nrf2 accumulates and translocates to the nucleus. There it heterodimerizes with small Maf proteins and binds ARE sequences in target gene promoters, inducing transcription of the canonical phase 2 / antioxidant response gene set.

Many phytochemicals work as Nrf2 activators through the same general mechanism: they are electrophiles that covalently modify Keap1 cysteine residues, releasing Nrf2 from degradation. Sulforaphane (the active broccoli-sprout phytochemical) and curcumin are the most-studied examples. The remarkable thing about Nrf2 activators is that they cause cells to mount a much larger antioxidant defense than the small initial insult would justify — the hormetic principle. A small electrophilic insult primes the cell to handle much larger future insults.

Back to Table of Contents

Betanin as an Nrf2 Activator

Betanin (the dominant betacyanin pigment of red beets) was identified as an Nrf2 activator in human liver cell lines by Krajka-Kuzniak and colleagues in a 2013 British Journal of Nutrition paper. In HepG2 hepatoma and Hep3B hepatocellular carcinoma cells, betanin at concentrations of 10–50 μM induced nuclear translocation of Nrf2 within 6 hours and increased mRNA and protein levels of GST, NQO1, and HO-1 within 24 hours. The induction was Nrf2-dependent — Nrf2 knockdown by siRNA abolished the effect.

The exact mechanism by which betanin activates Nrf2 is not fully established. Betanin has a 1,7-diazaheptamethine chromophore with an electron-rich indoline ring system. It could be acting as a direct electrophile on Keap1 cysteines, or it could be generating an indirect signal through partial oxidation to a more reactive intermediate. The functional consequence — Nrf2 activation and phase 2 enzyme induction — is consistent across multiple cell systems and animal models.

Importantly, the induction is dose-dependent in a hormetic manner: low to moderate doses of betanin induce cytoprotection, while very high doses can be pro-oxidant. The clinical implication is that the food-source dose of beets (one to two whole beets, or one cup of beetroot juice per day) is squarely in the cytoprotective range. Pharmacologic megadosing of isolated betanin extract is not necessary and may be counterproductive.

Back to Table of Contents

The Phase 2 Enzymes Induced by Betalain

The specific phase 2 enzymes induced by betanin in hepatocyte studies are the canonical Nrf2 target gene set:

• Glutathione S-transferase (GST) — conjugates glutathione to electrophilic carbon atoms on xenobiotic metabolites. Multiple GST isoforms (GSTA1, GSTM1, GSTP1) are induced. This is the dominant pathway for clearing the reactive intermediates of phase 1 metabolism, including the acetaminophen reactive metabolite NAPQI.
• NAD(P)H quinone dehydrogenase 1 (NQO1) — two-electron reduction of quinones to hydroquinones, bypassing the more dangerous one-electron reduction that generates semiquinone radicals. NQO1 is the workhorse for clearing endogenous quinones (catecholamine quinones, ubiquinone redox cycling) and environmental quinones.
• Heme oxygenase-1 (HO-1) — degrades heme to biliverdin, releasing iron and carbon monoxide. The downstream products (biliverdin, bilirubin, CO) have potent anti-inflammatory and cytoprotective effects. HO-1 is one of the most stress-responsive genes in the genome and is strongly induced by Nrf2 activators.
• Glutamate-cysteine ligase (GCL, both catalytic and modifier subunits) — the rate-limiting enzyme in glutathione biosynthesis. Induction of GCL is the primary mechanism by which Nrf2 activators raise intracellular glutathione stores, providing more substrate for GST and direct antioxidant defense.
• Thioredoxin reductase 1 (TXNRD1) and thioredoxin (TXN) — the second major intracellular reducing system after glutathione, responsible for keeping cellular proteins in their reduced functional state.
• Glutathione peroxidase (GPX) — enzymatically reduces hydrogen peroxide and lipid peroxides using glutathione as cofactor
• Catalase — reduces hydrogen peroxide to water and oxygen

The collective effect of inducing this gene set is that the hepatocyte (or any other cell expressing Nrf2 targets) becomes more resistant to oxidative and electrophilic insult. Cellular glutathione levels rise, conjugation capacity increases, and the reactive intermediates of phase 1 metabolism are cleared faster.

Back to Table of Contents

Betaine as a Methyl Donor — The BHMT Pathway

Beyond the betalain pigments, beets contain unusually high concentrations of betaine (also called trimethylglycine, TMG). At 114–297 mg per 100 g of fresh beet, the root is among the densest dietary sources, second only to wheat germ and quinoa. Betaine has a separate and complementary role in liver biochemistry as a methyl donor.

One-carbon (methyl-group) metabolism is central to liver biochemistry. The amino acid methionine, activated to S-adenosylmethionine (SAM, also called SAMe), is the universal methyl donor for hundreds of methyltransferase reactions including phosphatidylethanolamine N-methyltransferase (PEMT, which produces phosphatidylcholine), guanidinoacetate methyltransferase (producing creatine), DNA methyltransferases (epigenetic regulation), histone methyltransferases, and the catechol-O-methyltransferases that inactivate catecholamines.

After donating its methyl group, SAM becomes S-adenosylhomocysteine (SAH), which is hydrolyzed to homocysteine. Homocysteine must be remethylated back to methionine (or transsulfurated to cysteine for glutathione synthesis) or it accumulates and becomes cytotoxic. There are two parallel remethylation pathways:

1. The folate/B12-dependent pathway — methionine synthase uses 5-methyl-tetrahydrofolate (the active circulating folate) and vitamin B12 as cofactor to transfer a methyl group to homocysteine, regenerating methionine. This is the dominant pathway in most tissues.
2. The betaine-homocysteine methyltransferase (BHMT) pathway — uses betaine as the methyl donor, producing methionine and dimethylglycine (DMG). BHMT is expressed primarily in liver and kidney; it is the redundant backup pathway that becomes critical when folate or B12 are limited, when SAM demand is high, or when the folate-cycle is impaired by genetic polymorphisms.

Dietary betaine intake directly feeds the BHMT pathway. In folate-replete healthy adults, supplemental betaine reduces fasting plasma homocysteine by approximately 10–15%, and in patients with elevated baseline homocysteine, the reduction can be 20–30%. The Mirmiran 2020 meta-analysis pooled randomized trials of betaine supplementation and confirmed the consistent homocysteine-lowering effect.

The clinical significance of lowering homocysteine has been debated. Genetic studies (Mendelian randomization) suggest a causal role for moderately elevated homocysteine in cardiovascular and cerebrovascular disease, but trials of supplemental folate and B12 alone have failed to clearly reduce cardiovascular events. Betaine adds a parallel pathway that may help in patients with genetic folate-cycle impairments (MTHFR C677T or A1298C polymorphisms), but is not a universal hypertension or cardiovascular intervention.

Back to Table of Contents

Protection Against NAFLD and Hepatic Steatosis

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver condition in developed countries, affecting roughly 25% of adults in the United States. The disease spectrum runs from simple steatosis (fat accumulation in hepatocytes) through non-alcoholic steatohepatitis (NASH, with inflammation and hepatocyte injury) to fibrosis and cirrhosis. The driving mechanisms include insulin resistance, lipotoxic free fatty acid accumulation, mitochondrial dysfunction, oxidative stress, and chronic low-grade hepatic inflammation.

Betaine has direct anti-steatotic effects through multiple mechanisms. First, betaine supports phosphatidylcholine synthesis via the methylation of phosphatidylethanolamine to phosphatidylcholine by PEMT. Phosphatidylcholine is essential for the assembly and secretion of very-low-density lipoprotein (VLDL) from the hepatocyte. Without adequate phosphatidylcholine, fat that the hepatocyte synthesizes cannot be exported as VLDL and instead accumulates as intracellular triglyceride droplets — the hallmark of steatosis.

Second, betaine has osmolyte properties. It accumulates in hepatocytes (and many other cell types) and stabilizes protein conformation under osmotic and oxidative stress. This is the same mechanism by which kidney inner medullary cells use betaine to survive the extreme osmotic gradient of urinary concentration.

Third, the methyl-donor role of betaine maintains SAM-mediated methylation of regulatory proteins involved in lipid metabolism, including various transcription factors that control fatty acid oxidation and de novo lipogenesis.

Animal studies of betaine in NAFLD models consistently show reduced hepatic triglyceride, improved liver enzymes, and reduced fibrosis markers. The Wang 2017 paper in AJP-GI showed that betaine improved NAFLD and the associated hepatic insulin resistance in high-fat-diet rodents through SAM-mediated mechanisms. Human trials have been smaller and mixed; the conservative summary is that betaine appears to be helpful as part of a comprehensive NAFLD management approach but is not a stand-alone treatment.

The combination of Nrf2 activation (from betalain pigments) and methyl-donor support (from betaine) means that a serving of beets simultaneously upregulates antioxidant and conjugation defenses while supporting the methylation pathways needed for hepatic lipid export. The two mechanisms are complementary and would not be expected from a single phytochemical class.

Back to Table of Contents

Animal Models — APAP, CCl₄, and High-Fat Diet

The protective effect of beetroot in liver-toxicity models has been demonstrated across multiple animal systems:

• Acetaminophen (APAP) hepatotoxicity — Vasconcelos and colleagues (2017, Phytomedicine) showed that beetroot juice pre-treatment in rats subsequently challenged with hepatotoxic acetaminophen produced markedly reduced ALT and AST elevation, reduced histological evidence of centrilobular necrosis, upregulated Nrf2 nuclear translocation, increased GST and HO-1 expression, and downregulated NF-kB inflammatory signaling. The mechanism is consistent with the Nrf2 activation pathway described above — pre-induction of phase 2 enzymes allows faster clearance of NAPQI before it depletes glutathione.
• Carbon tetrachloride (CCl₄) hepatotoxicity — CCl₄ is the classical research-model hepatotoxin, producing centrilobular necrosis through CYP2E1-mediated generation of trichloromethyl radicals. Multiple rodent studies have shown that beetroot juice or betalain extract pre-treatment reduces CCl₄-induced hepatocellular damage as measured by liver enzymes, lipid peroxidation markers, and histology.
• High-fat diet-induced NAFLD — betaine and beet-juice feeding in high-fat-diet models reduces hepatic triglyceride accumulation, improves insulin sensitivity, and reduces NAFLD activity score. The Wang 2017 AJP-GI paper is the most thorough mechanistic study.
• Aflatoxin B1 hepatocarcinogenesis — aflatoxin B1 is a CYP3A4 substrate metabolized to a DNA-damaging epoxide. GST-mediated conjugation is the primary detoxification route. Beetroot feeding increases GST activity in rodent liver and reduces aflatoxin-DNA adduct formation in cell models.
• Esophageal carcinogenesis model — Lechner and colleagues (2010, Journal of Medicinal Food) showed that drinking water containing red beetroot food color antagonized esophageal carcinogenesis in N-nitrosomethylbenzylamine-treated rats. This is a chemoprevention model showing that betalain pigments at dietary concentrations have measurable anti-carcinogenic effect.

Translation to human clinical trials remains limited — the cardiovascular and athletic-endurance applications have far more human trial data than the hepatoprotection application. The mechanistic case is strong, but definitive human RCTs in NAFLD or other liver conditions are not yet available.

Back to Table of Contents

Clinical Applications and Practical Dosing

Beets are best thought of as a complementary food in a comprehensive liver-support strategy rather than a stand-alone hepatoprotectant. Practical applications:

• NAFLD / NASH adjunct nutrition — one to two servings of beets per day (one whole roasted beet or one cup of beet juice) as part of a Mediterranean or low-carbohydrate dietary pattern. Pair with other Nrf2-activating foods (broccoli sprouts, turmeric, green tea) for additive effect. Combine with the other established NAFLD nutritional interventions: weight loss of 7–10% body weight, coffee 2–4 cups per day, omega-3 from fatty fish, vitamin E in non-diabetic biopsy-confirmed NASH.
• Pre-medication for known hepatotoxic agents — patients undergoing chemotherapy with hepatotoxic agents, methotrexate therapy, isoniazid therapy, or who use chronic acetaminophen may benefit from regular beet intake as part of a phase-2-supportive diet. The mechanism is plausible but the clinical magnitude is unproven.
• Recovery from acute viral hepatitis — once acute inflammation is settling, the Nrf2-supportive nutrient pattern (including beets) can help restore hepatic antioxidant defenses and glutathione stores.
• MTHFR polymorphisms with elevated homocysteine — patients with documented MTHFR C677T homozygous variant and elevated homocysteine despite folate and B12 repletion often benefit from added betaine through the BHMT bypass pathway. Beet juice is a good dietary source; supplemental TMG (trimethylglycine) at 500–3000 mg/day is the pharmacologic option.
• Chronic alcohol use — alcohol depletes hepatic glutathione, impairs methylation, and drives fatty liver. Beetroot, with its dual Nrf2-activation and methyl-donor effects, directly addresses both mechanisms. Not a substitute for reducing alcohol intake, but a useful nutritional adjunct.
• Environmental exposure mitigation — people with heavy exposure to industrial chemicals, pesticides, or polluted air can benefit from chronic upregulation of phase 2 enzymes through dietary Nrf2 activators including beets. The mechanism translates plausibly to humans but precise clinical magnitude is unknown.

Back to Table of Contents

Cautions and Drug Interactions

• Oxalates and kidney stones — beet root is moderate (about 76 mg oxalate per 100 g) and beet greens are very high (610 mg per 100 g). Patients with calcium-oxalate stones should moderate intake and pair with calcium-containing foods at the same meal to reduce oxalate absorption.
• Existing severe liver disease — in decompensated cirrhosis, the metabolism of any food intervention is unpredictable and isolated supplements should be avoided. Whole food beets in modest amounts are fine.
• Concurrent NAC (N-acetylcysteine) therapy — both work to support hepatic glutathione synthesis through different mechanisms. They are complementary rather than redundant and can be used together.
• Methotrexate hepatotoxicity — methotrexate impairs folate metabolism. The folate-cycle disruption is partially bypassed by the betaine-BHMT pathway, so beets and supplemental betaine may be specifically helpful in methotrexate users with rising liver enzymes. Discuss with the prescriber before combining.
• Drug-metabolism interactions — phase 2 enzyme induction can theoretically increase the clearance of drugs metabolized by glucuronidation, sulfation, or glutathione conjugation. The magnitude of this effect from food-form beet intake is small and clinically meaningful interactions have not been reported. Pharmacologic-dose isolated betalain or betaine supplements are more likely to alter drug metabolism than food-form beets.
• Beeturia (red urine) — harmless genetic variant in about 10–14% of population. Reassuring patients about this is important.
• Combining with high-dose iron supplements — an older theory linked beeturia to iron deficiency; this has not held up, but the broader principle that iron homeostasis influences beet pigment metabolism is reasonable. No specific clinical adjustment needed.

Back to Table of Contents

Key Research Papers

1. Krajka-Kuzniak V et al. (2013). Betanin, a beetroot component, induces nuclear factor erythroid-2-related factor 2-mediated expression of detoxifying/antioxidant enzymes in human liver cell lines. British Journal of Nutrition 110:2138-2149. — PubMed 23656786
2. Vasconcelos MG et al. (2017). Beetroot juice prevents acetaminophen-induced hepatotoxicity in adult rats by upregulating Nrf2 and downregulating NF-kappaB. Phytomedicine 26:38-47. — PubMed 28236570
3. Vulic JJ et al. (2014). Antioxidant and cell-protective effects of purified red beet (Beta vulgaris) betalains on HepG2 cells. Food & Function 5:2154-2162. — PubMed 25144526
4. Wang S et al. (2017). Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. American Journal of Physiology — Gastrointestinal & Liver Physiology 313:G56-G66. — PubMed 27932505
5. Esatbeyoglu T et al. (2015). Betanin — a food colorant with biological activity. Molecular Nutrition & Food Research 59:36-47. — PubMed 25266247
6. Lechner JF et al. (2010). Drinking water with red beetroot food color antagonizes esophageal carcinogenesis in N-nitrosomethylbenzylamine-treated rats. Journal of Medicinal Food 13:733-739. — PubMed 20828311
7. Kanner J, Harel S, Granit R (2001). Betalains — a new class of dietary cationized antioxidants. Journal of Agricultural and Food Chemistry 49:5178-5185. — PubMed 11714316
8. Clifford T et al. (2015). The potential benefits of red beetroot supplementation in health and disease. Nutrients 7:2801-2822. — PubMed 25875121
9. Ma N et al. (2013). Nrf2 pathway and betaine: mechanism for hepatoprotection in rodent models. Journal of Pharmacology Sciences. — PubMed: Betaine Nrf2 hepatoprotection
10. Olthof MR, Verhoef P (2005). Effects of betaine intake on plasma homocysteine concentrations and consequences for health. Current Drug Metabolism 6:15-22. — PubMed 15720203
11. Tesoriere L et al. (2003). Absorption, excretion, and distribution in low-density lipoproteins of dietary antioxidant betalains. American Journal of Clinical Nutrition 78:941-945. — PubMed 14668265
12. Itoh K, Yamamoto M et al. (1999). Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes & Development. — PubMed: Itoh/Yamamoto Keap1/Nrf2 1999

PubMed Topic Searches

• PubMed: Betanin Nrf2 phase 2
• PubMed: Beetroot hepatoprotection
• PubMed: Betaine BHMT pathway
• PubMed: Betaine fatty liver
• PubMed: GST induction diet

Back to Table of Contents

Connections

• Beets Overview
• Beets Benefits Hub
• Beets & Blood Pressure
• Beets Athletic Endurance
• Beets Pigments
• Hepatology
• NAFLD / Fatty Liver
• N-Acetylcysteine (NAC)
• Glutathione
• Milk Thistle
• Vitamin E
• Turmeric
• Broccoli Sprouts (Sulforaphane)
• Detoxification
• All Food

Back to Table of Contents